Lexaria Bioscience: DehydraTECH-CBD shows better seizure control at lower doses vs. Epidiolex in animal study

Lexaria Bioscience Corp.

Pilot study: at 50 mg/kg, only DehydraTECH-CBD showed seizure reduction; at 75 mg/kg, full elimination in 66.6% of animals vs. 50% for Epidiolex.
Time to peak efficacy: at 30 min, 50% of DehydraTECH-CBD animals had partial/full seizure elimination vs. 0% for Epidiolex; at 60 min, 87.5% vs. 62.5%.
ED50 study (dose for 50% seizure inhibition) is underway; results will be reported separately.
Study EPIL-A21-1 uses MES model in rats; fully funded by Lexaria and performed by a US independent lab.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.